The Cooper Companies, Inc. announced a leadership transition on October 27, 2026, resulting in the resignation of President and Chief Executive Officer Albert G. White III. Mr. White has agreed to remain employed as a strategic advisor through April 1, 2027, to assist with the transition of his responsibilities.
Walter M. Rosebrough, Jr., an independent member of the Board of Directors, has been appointed Executive Chair of the Board on an interim basis, effective immediately. Mr. Rosebrough will assume direct oversight of day-to-day operations until a permanent Chief Executive Officer is appointed. The Board has formed a CEO Search Committee, comprised of Lawrence E. Kurzius, Cynthia L. Lucchese, and Teresa S. Madden, to oversee the search for a permanent CEO with support from the professional search firm Russell Reynolds.
In addition to the leadership changes, the Company announced a Board refreshment. Shlomo (Shlomi) Nachman has been appointed as an independent director, effective December 8, 2026, to serve until the Company’s 2027 Annual Meeting of Stockholders. Mr. Nachman is a former Johnson & Johnson executive with over 27 years of healthcare experience, most recently serving as Company Group Chairman of the Cardiovascular and Specialty Solutions & Vision Group.
Three current directors, Barbara Carbone, Colleen E. Jay, and Robert S. Weiss, have notified the Company of their decision not to stand for reelection at the 2027 Annual Meeting. As a result, the Company intends to nominate seven directors for election at the upcoming meeting, including Mr. Rosebrough and Mr. Nachman.
The Company reaffirmed its full-year fiscal 2026 guidance provided on September 9, 2026.
